← Leaderboards
Mark J Levis
Johns Hopkins University
$4,468,842
Attributed
$4,468,842
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $754.3K · FY2005–13$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$4,468,842 · 4
By mechanism
P50$2,095,210 · 2
R01$1,681,082 · 1
K08$692,550 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Richard J Jones$17,555,212
- Donald Small$15,602,119
- Robert John Arceci$2,646,019
- Curt I Civin$14,314,285
- Hyam Isaac Levitsky$7,128,026
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsLeukemiaClinical ResearchChemotherapySamplingTyrosine Kinase InhibitorResistanceMutationIn VitroReceptor Protein-Tyrosine KinasesFlt3 InhibitorCytotoxicSmall MoleculeBiological ModelsBlast CellInhibitor/AntagonistPharmaceutical PreparationsFlt3 InhibitionFlt3 GeneCellsResponseChemotherapeutic AgentAnimal ModelLeukemia, Myelocytic, Acute
Grant awards (16)
Incorporating FLT3 Inhibitors into Acute Myeloid Leukemia(AML)Treatment Regimens$297,599
P50 · FY2013 · CA · contact PI
Incorporating FLT3 Inhibitors into AML Treatment Regimens$347,806
P50 · FY2012 · CA · contact PI
Incorporating FLT3 inhibitors into AML treatment regimens$330,091
R01 · FY2012 · CA · contact PI
Incorporating FLT3 Inhibitors into AML Treatment Regimens$387,019
P50 · FY2011 · CA · contact PI
Incorporating FLT3 inhibitors into AML treatment regimens$330,091
R01 · FY2011 · CA · contact PI
Incorporating FLT3 Inhibitors into AML Treatment Regimens$381,038
P50 · FY2010 · CA · contact PI
Incorporating FLT3 inhibitors into AML treatment regimens$340,300
R01 · FY2010 · CA · contact PI
Incorporating FLT3 Inhibitors into AML Treatment Regimens$414,005
P50 · FY2009 · CA · contact PI
Incorporating FLT3 inhibitors into AML treatment regimens$340,300
R01 · FY2009 · CA · contact PI
Incorporating FLT3 inhibitors into AML treatment regimens$340,300
R01 · FY2008 · CA · contact PI
Incorporating FLT3 Inhibitors into AML Treatment Regimens$267,743
P50 · FY2008 · CA · contact PI
Targeting FLT3 as a Novel Specific Therapy for Leukemia$138,510
K08 · FY2007 · CA · contact PI
Targeting FLT3 as a Novel Specific Therapy for Leukemia$138,510
K08 · FY2006 · CA · contact PI
Targeting FLT3 as a Novel Specific Therapy for Leukemia$138,510
K08 · FY2005 · CA
Targeting FLT3 as a Novel Specific Therapy for Leukemia$138,510
K08 · FY2004 · CA
Targeting FLT3 as a Novel Specific Therapy for Leukemia$138,510
K08 · FY2003 · CA